Valneva SE (VLA) - Net Assets
Based on the latest financial reports, Valneva SE (VLA) has net assets worth €76.70 Million EUR (≈ $89.67 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€372.01 Million ≈ $434.92 Million USD) and total liabilities (€295.31 Million ≈ $345.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check VLA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €76.70 Million |
| % of Total Assets | 20.62% |
| Annual Growth Rate | 16.77% |
| 5-Year Change | -37.76% |
| 10-Year Change | 6.11% |
| Growth Volatility | 150.91 |
Valneva SE - Net Assets Trend (2005–2025)
This chart illustrates how Valneva SE's net assets have evolved over time, based on quarterly financial data. See VLA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Valneva SE (2005–2025)
The table below shows the annual net assets of Valneva SE from 2005 to 2025. For live valuation and market cap data, see VLA stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €106.17 Million ≈ $124.12 Million |
-41.43% |
| 2024-12-31 | €181.25 Million ≈ $211.90 Million |
+41.33% |
| 2023-12-31 | €128.25 Million ≈ $149.93 Million |
-41.65% |
| 2022-12-31 | €219.80 Million ≈ $256.97 Million |
+28.85% |
| 2021-12-31 | €170.58 Million ≈ $199.43 Million |
+120.33% |
| 2020-12-31 | €77.42 Million ≈ $90.51 Million |
-42.72% |
| 2019-12-31 | €135.15 Million ≈ $158.01 Million |
-5.61% |
| 2018-12-31 | €143.19 Million ≈ $167.40 Million |
+54.51% |
| 2017-12-31 | €92.67 Million ≈ $108.34 Million |
-7.38% |
| 2016-12-31 | €100.05 Million ≈ $116.97 Million |
-30.68% |
| 2015-12-31 | €144.34 Million ≈ $168.74 Million |
+15.98% |
| 2014-12-31 | €124.44 Million ≈ $145.49 Million |
-13.65% |
| 2013-12-31 | €144.11 Million ≈ $168.48 Million |
+450.17% |
| 2012-12-31 | €26.19 Million ≈ $30.62 Million |
-35.24% |
| 2011-12-31 | €40.45 Million ≈ $47.28 Million |
-8.68% |
| 2010-12-31 | €44.29 Million ≈ $51.78 Million |
+96.58% |
| 2009-12-31 | €22.53 Million ≈ $26.34 Million |
-17.83% |
| 2008-12-31 | €27.42 Million ≈ $32.05 Million |
-5.49% |
| 2007-12-31 | €29.01 Million ≈ $33.92 Million |
+522.67% |
| 2006-12-31 | €4.66 Million ≈ $5.45 Million |
-2.49% |
| 2005-12-31 | €4.78 Million ≈ $5.59 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Valneva SE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67580100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €26.03 Million | 24.52% |
| Other Comprehensive Income | €40.74 Million | 38.37% |
| Other Components | €718.52 Million | 676.77% |
| Total Equity | €106.17 Million | 100.00% |
Valneva SE Competitors by Market Cap
The table below lists competitors of Valneva SE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Duta Pertiwi Tbk
JK:DUTI
|
$433.61 Million |
|
Minera Alamos Inc
V:MAI
|
$433.74 Million |
|
Qinghai Spring Medicinal Resources Technology Co Ltd
SHG:600381
|
$433.82 Million |
|
LB Foster Company
NASDAQ:FSTR
|
$434.14 Million |
|
Sports Toto Berhad
KLSE:1562
|
$433.37 Million |
|
Zedcor Energy
V:ZDC
|
$433.31 Million |
|
Brainsway Ltd
TA:BWAY
|
$433.31 Million |
|
Sinopec Oilfield Service Corporation
F:YIZH
|
$433.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valneva SE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 181,253,000 to 106,168,000, a change of -75,085,000 (-41.4%).
- Net loss of 115,192,000 reduced equity.
- Other comprehensive income increased equity by 588,000.
- Other factors increased equity by 39,519,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-115.19 Million | -108.5% |
| Other Comprehensive Income | €588.00K | +0.55% |
| Other Changes | €39.52 Million | +37.22% |
| Total Change | €- | -41.43% |
Book Value vs Market Value Analysis
This analysis compares Valneva SE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.61x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.87x to 3.61x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | €0.47 | €2.28 | x |
| 2006-12-31 | €0.46 | €2.28 | x |
| 2007-12-31 | €2.22 | €2.28 | x |
| 2008-12-31 | €1.63 | €2.28 | x |
| 2009-12-31 | €1.54 | €2.28 | x |
| 2010-12-31 | €2.53 | €2.28 | x |
| 2011-12-31 | €1.92 | €2.28 | x |
| 2012-12-31 | €1.23 | €2.28 | x |
| 2013-12-31 | €3.66 | €2.28 | x |
| 2014-12-31 | €2.24 | €2.28 | x |
| 2015-12-31 | €1.98 | €2.28 | x |
| 2016-12-31 | €1.34 | €2.28 | x |
| 2017-12-31 | €1.20 | €2.28 | x |
| 2018-12-31 | €1.75 | €2.28 | x |
| 2019-12-31 | €1.47 | €2.28 | x |
| 2020-12-31 | €0.85 | €2.28 | x |
| 2021-12-31 | €1.75 | €2.28 | x |
| 2022-12-31 | €1.90 | €2.28 | x |
| 2023-12-31 | €0.93 | €2.28 | x |
| 2024-12-31 | €1.24 | €2.28 | x |
| 2025-12-31 | €0.63 | €2.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valneva SE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -108.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.95%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 3.76x
- Recent ROE (-108.50%) is below the historical average (-31.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -25.53% | -40.52% | 0.21x | 3.06x | €-1.70 Million |
| 2006 | -5.22% | -10.43% | 0.16x | 3.20x | €-708.90K |
| 2007 | -11.59% | -388.22% | 0.02x | 1.36x | €-6.26 Million |
| 2008 | -8.71% | -69.89% | 0.08x | 1.51x | €-5.13 Million |
| 2009 | -27.27% | -198.45% | 0.07x | 2.04x | €-8.40 Million |
| 2010 | -17.98% | -94.84% | 0.11x | 1.80x | €-12.39 Million |
| 2011 | -10.93% | -43.06% | 0.14x | 1.81x | €-8.46 Million |
| 2012 | -56.66% | -432.56% | 0.06x | 2.05x | €-17.46 Million |
| 2013 | -16.73% | -79.19% | 0.12x | 1.77x | €-38.52 Million |
| 2014 | -21.11% | -71.15% | 0.16x | 1.83x | €-38.72 Million |
| 2015 | -14.28% | -26.31% | 0.28x | 1.91x | €-35.05 Million |
| 2016 | -49.16% | -52.29% | 0.45x | 2.07x | €-59.19 Million |
| 2017 | -12.39% | -10.91% | 0.56x | 2.04x | €-20.75 Million |
| 2018 | 2.28% | 2.89% | 0.49x | 1.61x | €-11.05 Million |
| 2019 | -1.29% | -1.38% | 0.48x | 1.96x | €-15.26 Million |
| 2020 | -83.17% | -58.37% | 0.25x | 5.80x | €-72.14 Million |
| 2021 | -43.04% | -21.09% | 0.43x | 4.79x | €-90.48 Million |
| 2022 | -65.19% | -39.66% | 0.58x | 2.83x | €-165.26 Million |
| 2023 | -79.09% | -65.99% | 0.33x | 3.59x | €-114.25 Million |
| 2024 | -6.76% | -7.22% | 0.34x | 2.76x | €-30.37 Million |
| 2025 | -108.50% | -65.95% | 0.44x | 3.76x | €-125.81 Million |
Industry Comparison
This section compares Valneva SE's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $33,345,754
- Average return on equity (ROE) among peers: -383.86%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valneva SE (VLA) | €76.70 Million | -25.53% | 3.85x | $433.53 Million |
| Abionyx Pharma SA (ABNX) | $6.67 Million | 27.74% | 0.54x | $104.56 Million |
| Abivax SA (ABVX) | $1.88 Million | -3227.42% | 37.98x | $7.75 Billion |
| Adocia (ADOC) | $42.76 Million | -18.46% | 0.84x | $93.64 Million |
| Aelis Farma SA (AELIS) | $-710.00K | 0.00% | 0.00x | $17.24 Million |
| Biophytis S.A. (ALBPS) | $5.71 Million | -587.66% | 5.36x | $752.91K |
| Cellectis (ALCLS) | $274.05 Million | -23.32% | 0.21x | $228.29 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $18.78 Million |
| Genoway (ALGEN) | $5.10 Million | 5.12% | 0.91x | $31.09 Million |
| Integragen (ALINT) | $1.76 Million | -14.58% | 2.14x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.08 Million | 0.00% | 0.00x | $1.80 Million |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more